FONDAZIONE POLIAMBULANZA

Their core work

Fondazione Poliambulanza is a hospital foundation based in Brescia, Italy, that combines clinical care with applied research. Their primary research contributions center on clinical trials in orthopaedic surgery and regenerative medicine — specifically cell therapy for hip fracture recovery — and on maternal-fetal health, studying chemical safety during pregnancy and placental biology. They also contributed to smart energy demand response in hospital/building settings, reflecting their operational interest in facility management alongside their clinical mission.

What they specialise in

How they've shifted over time

Their earliest H2020 involvement (2016) was in energy demand response through DR-BOB, likely contributing their hospital campus as a real-world testbed. From 2018 onward, they shifted entirely to health and clinical research — first with an advanced cell therapy clinical trial (HIPGEN), then into maternal-fetal toxicology and placental science (LIFESAVER). The trajectory shows a clear consolidation toward clinical health research, particularly around placental biology and patient recovery.

Moving firmly into clinical health research with a niche in placental biology — both for regenerative cell therapy and for maternal drug safety — making them a strong clinical partner for translational medicine projects.

How they like to work

Fondazione Poliambulanza has never coordinated an H2020 project, consistently joining as a participant or third party. This suggests they serve as a clinical site and domain expert rather than a project management hub. With 41 unique partners across 19 countries from just 3 projects, they operate within large, well-connected consortia and are comfortable in international, multi-partner settings.

Despite a small project portfolio, they have collaborated with 41 distinct partners across 19 countries, reflecting their participation in large European consortia. Their network spans broadly across the EU with no obvious geographic concentration.

What sets them apart

As a hospital foundation rather than a university, Poliambulanza offers direct access to clinical infrastructure, patient cohorts, and real-world care settings — assets that pure research institutes cannot easily provide. Their dual expertise in orthopaedic cell therapy trials and maternal-fetal pharmacology gives them a distinctive niche at the intersection of regenerative medicine and reproductive health. For consortium builders, they bring the credibility of a clinical site that can run Phase III studies and validate treatments in practice.

Highlights from their portfolio

• HIPGEN
  A Phase III clinical study testing an advanced cell therapy (placenta-expanded stromal cells) for hip fracture recovery — one of few hospital-led regenerative medicine trials at this stage.
• LIFESAVER
  Addresses a critical gap in chemical and drug safety for pregnant women, combining in vitro placental models with bioprinting and biodigital twin approaches.